PCI has been one of the most common choice of treatments for patients with coronary artery
disease, and studies indicated that intensive statin treatment before PCI could reduce
adverse events as comparing to the placebo. In China, statin with regular dose is currently
applied to the patients admitted for Non-ST-elevation acute coronary syndrome (ACS). Here we
hypothesize that intensive statin treatment with arovastatin before PCI could further reduce
clinical adverse events.